Cohort Profile: Cohort of Norway (CONOR)

Næss, Øyvind; Søgaard, Anne Johanne; Arnesen, Egil; Beckstrøm, Anne Cathrine; Bjertness, Espen; Engeland, Anders; Hjort, Peter Fredrik; Holmen, Jostein; Magnus, Per; Njølstad, Inger; Tell, Grethe S.; Vatten, Lars J.; Vollset, Stein Emil; Aamodt, Geir

doi:10.1093/ije/dym217

Cited by 186 publications

(207 citation statements)

References 14 publications

Supporting

Mentioning

202

Contrasting

Unclassified

Order By: Relevance

“…The details of both these cohorts have been described previously [16,17]. In brief, CONOR is a collaborative project between the Norwegian Institute of Public Health and universities in Oslo, Bergen, Trondheim, and Tromsø, where data from 10 regional health surveys have been combined into one national database.…”

Section: Study Design and Participantsmentioning

confidence: 99%

Metabolic syndrome and esophageal and gastric cancer

Lin

Ness-Jensen

Hveem

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

Background The role of the metabolic syndrome in the etiology of esophageal and gastric cancer is unclear. Methods This was a large nationwide cohort study based on data from 11 prospective population-based cohorts in Norway with long-term follow-up, the Cohort of Norway (CONOR) and the third Nord-Trøndelag Health Study (HUNT3). The metabolic syndrome was assessed by objective anthropometric and metabolic biochemical measures and was defined by the presence of at least three of the following five factors: increased waist circumference, elevated triglycerides, low highdensity lipoprotein cholesterol, hypertension and high glucose. Newly diagnosed cases of esophageal adenocarcinoma, esophageal squamous-cell carcinoma and gastric adenocarcinoma were identified from the Norwegian Cancer Registry. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models with adjustment for potential confounders. Result Among 192,903 participants followed up for an average of 10.6 years, 62 developed esophageal adenocarcinoma, 64 had esophageal squamous-cell carcinoma and 373 had gastric adenocarcinoma. The metabolic syndrome was significantly associated with an increased risk of gastric adenocarcinoma (HR 1.44, 95 % CI 1.14-1.82), but not associated with esophageal adenocarcinoma (HR 1.32, 95 % CI 0.77-2.26) or esophageal squamous-cell carcinoma (HR 1.08, 95 % CI 0.64-1.83). Increased waist circumference was associated with an increased HR of esophageal adenocarcinoma (HR 2.48,. No significant association was found between any single component of the metabolic syndrome and risk of esophageal squamous-cell carcinoma. High waist circumference (HR 1.71, 95 % CI 1.05-2.80), hypertension (HR 2.41, 95 % CI 1.44-4.03) and non-fasting glucose (HR 1.74, 95 % CI 1.18-2.56) were also related to an increased risk of gastric adenocarcinoma in women, but not in men. Conclusion Metabolic syndrome was associated with an increased risk of gastric adenocarcinoma in women. Of the individual components of the metabolic syndrome, high waist circumference was positively associated with risk of esophageal adenocarcinoma. Positive associations were also observed for women between high waist circumference, hypertension, high non-fasting glucose and risk of gastric adenocarcinoma. However, further evidence is warranted due to the limited number of cases and the inability to effectively identify gastric cardia adenocarcinoma.

show abstract

Section: Study Design and Participantsmentioning

confidence: 99%

Metabolic syndrome and esophageal and gastric cancer

Lin

Ness-Jensen

Hveem

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…We found that the majority of excess risk associated with having both conditions, compared to neither condition, was mediated through HDL-C and nonHDL-C. HDL-C and nonHDL-C are both highly related to triglyceride levels and to an enlarged waist circumference [17]. Also, HDL-C and nonHDL-C provide important information about underlying lipoprotein metabolism in which the need for additional consideration of triglyceride levels becomes less important [23].…”

Section: Discussionmentioning

confidence: 99%

“…Participants in at least one population-based regional health screening of Cohort Norway (CONOR) between 1994 and 2003 formed the baseline of the prospective study, details of which are described elsewhere [17,18]. Of a total of 309,742 invitations for CONOR study participation, 59% (181,891) participated, of whom 173,243 men and women attended at least one health screening.…”

Section: Methodsmentioning

confidence: 99%

Hypertriglyceridemic-Waist Phenotype is a Useful Global Assessment Tool for Predicting Acute Myocardial Infarction

Egeland¹,

Igland²,

Nygård³

et al. 2015

J Cardiovasc Dis Diagn

View full text Add to dashboard Cite

Research ArticleOpen Access strongly with post-prandial remnant lipoproteins, and that non-fasting triglycerides are superior to fasting triglycerides in characterizing the usual post-prandial state and its' associated risks [13,14]. Also, it is the remnant lipoproteins associated with elevated triglycerides and not the triglycerides, per se, that are considered atherogenic [15,16]. The presence of an enlarged waist with elevated triglyceride levels could identify individuals unable to clear and store excess triglycerides from over-nutrition and, therefore, identify individuals who are more likely to be chronically exposed to elevated remnant lipoproteins than individuals without the phenotype [1].Given the strong association of the hypertriglyceridemic-waist phenotype with insulin resistance and that elevated non-fasting triglycerides associate with greater exposures to atherogenic remnant lipoproteins, we evaluated, prospectively, the risk of incident acute IntroductionThe presence of hypertriglyceridemia with an elevated waist circumference, referred to as the hypertriglyceridemic-waist phenotype, is considered a proxy indicator of visceral fat which is now recognized to have greater metabolic consequences than that attributed to subcutaneous fat alone [1]. The phenotype has also been proposed to be a simpler alternative to the metabolic syndrome, and there has, therefore, been growing research interest in exploring the utility of the hypertriglyceridemic-waist phenotype as a predictor of cardiometabolic risk [2]. Numerous studies have identified the phenotype as being a strong associate and determinant of insulin resistance and diabetes in cross-sectional and prospective studies [3][4][5][6][7]. While a few prospective studies have evaluated the association between the phenotype and cardiovascular disease (CVD), the results of these studies are highly variable [8][9][10][11][12]. Thus, the usefulness of the phenotype as an independent predictor of CVD beyond classical CVD risk factors is not yet established.In addition, data suggest that non-fasting triglycerides correlate AbstractBackground: There has been growing research interest in exploring the utility of the hypertriglyceridemicwaist phenotype as a predictor of cardio-metabolic risk. To date, prospective studies evaluating the phenotype as a predictor of cardiovascular disease have provided variable results. Objectives:To evaluate the usefulness of the hypertriglyceridemic-waist phenotype as an independent predictor of acute myocardial infarction beyond classical cardiovascular disease risk factors in a homogeneous Norwegian population. Methods:Norwegian health survey (Cohort Norway) participants (n=116,111), free of heart disease in 1994-2003, were followed through 2009 by record linkages to The Cause of Death Registry and hospital discharge diagnoses through the Cardiovascular disease in Norway project. Cox proportional hazards analyses adjusted for conventional risk factors.Results: During a mean follow-up of 11.5 yrs (SD=2.8), 3,624 participants...

show abstract

“…Actuellement, l'épidémiologie fait face à la nécessité de développer des études d'une taille autrefois inimaginable. Qu'il s'agisse de mettre en évidence des risques de faible ampleur associés à l'exposition à des agents potentiellement pathogènes, d'évaluer l'efficacité d'interventions dont on attend des bénéfices d'ampleur modeste, ou de décrire la distribution et l'évolution d'événements peu fréquents, ce sont aujourd'hui des études cas-témoins en [2], le projet UK Biobank [3] qui a mis en place le suivi prospectif de 500 000 personnes, et la Norvegian Mother and Child Cohort Study qui a inclus 100 000 femmes à la 18 e semaine de grossesse puis leurs 100 000 nouveau-nés, ainsi que 70 000 pères, soit au total 270 000 personnes [4]. La Nurses' Health Study a été mise en place aux États-Unis dès 1976 et assure le suivi prospectif de près de 250 000 infirmières [5].…”

Section: Le Principe Des Cohortes éPidémiologiquesunclassified